Lin Han

Lin Han

Auto-generated profile, based on publicly available information

Lin Han

Yunnan Observatories (YNAO), Chinese Academy of Sciences (CAS), Kunming, 650216, People's Republic of China

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2024 in The Astrophysical Journal Letters
Verified
Journal Article
Open access
Jujia ZhangJujia Zhang
Jujia Zhang
LDLuc Dessart
Luc Dessart
XWXiaofeng Wang
Xiaofeng Wang
QZQian Zhai
Qian Zhai
YYYi Yang
Yi Yang
SYShengyu Yan
Shengyu Yan
We present early-time, hour-to-day cadence spectroscopy of the nearby Type II supernova (SN II) 2024ggi, which was discovered at a phase when the SN shock had just emerged from the red supergiant (RSG) progenitor star. Over the first few days after the first light, SN 2024ggi exhibited prominent narrow emission lines formed through intense and persistent photoionization of the nearby circumstellar material (CSM). In the first 63 hr, spectral lines of He, C, N, and O revealed a rapid rise in ionization as a result of the progressive sweeping up of the CSM by the shock. The duration of the IIn-like spectra indicates a dense and relatively confined CSM distribution extending up to ∼4 × 1014 cm. Spectral modeling reveals that a CSM mass-loss rate at this region exceeding 5 × 10−3 M ⊙ yr−1 is required to reproduce low-ionization emissions, which dramatically exceeds that of an RSG. Analyzing the Hα emission shift implies the velocity of the unshocked outer CSM to be between 20 and 40 km s−1, matching the typical wind velocity of an RSG. The differences between the inner and outer layers of the CSM and an RSG progenitor highlight a complex mass-loss history before the explosion of SN 2024ggi.

1 September 2013 in Pharmacological Reports
Verified
Journal Article
Open access
BZBingbing Zhu
Bingbing Zhu
YJYuanmeng Jin
Yuanmeng Jin
LHLin Han
Lin Han
HCHui Chen
Hui Chen
FZFang Zhong
Fang Zhong
NCNan Chen
Nan Chen
The ubiquitin proteasome pathway plays a pivotal role in controlling cell proliferation, apoptosis and differentiation in a variety of normal and tumor cells. This study aimed to investigate the role of a proteasome inhibitor on proliferation, apoptosis and related proteins in renal interstitial fibroblasts (NRK-49F). NRK-49F cells were induced using transforming growth factor-β1 (TGF-β1) and pretreated with the proteasome inhibitor MG-132. Cell proliferation was measured using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). The cell cycle and apoptosis were analyzed using flow cytometry. Apoptosis was also analyzed using a DNA ladder. The protein expression of p53, p27, p21, caspase-3, Bcl-2 and Bax was examined using western blots. The results showed that TGF-β1 (5 ng/ml) can stimulate the proliferation of NRK-49F cells.MG-132 (0.25-5 μM) inhibited TGF-β1-induced proliferation in a dose-dependent manner through G1-arrest; TGF-β1 alone did not induce apoptosis (3.8 ± 0.4% vs. 4.7 ± 1.6%). However, pretreatment with MG-132 significantly induced apoptosis in TGF-b1-stimulated NRK-49F cells in a dose-dependent manner. A typical DNA ladder was also confirmed in these two groups. Western blot analysis showed that MG-132 activated p53, p21, caspase-3 and Bax, and inhibited Bcl-2 in a dose-dependent manner, while p27 expression remained unchanged. A proteasome inhibitor inhibited proliferation and induced apoptosis in renal interstitial fibroblasts stimulated by TGF-β1. The mechanism may relate to the p53, p21, caspase-3, Bcl-2 and Bax pathways. Our results suggest that a proteasome inhibitor could be a new strategy to treat renal interstitial fibrosis.

9 January 2023 in The Heart Surgery Forum
Verified
Journal Article
Open access
PDF file
QCQian Chen
Qian Chen
NLNing Li
Ning Li
MQMing Qin
Ming Qin
XXxiangyang xu
xiangyang xu
KZKeng Zhong
Keng Zhong
ZXZhiyun Xu
Zhiyun Xu
Background: Defecation delay is a common symptom in patients after tricuspid valve replacement (TVR). Previous studies have demonstrated that defecation delay was associated with worse clinical outcomes of critically ill patients. Our study aimed to investigate the incidence and risk factors of defecation delay in patients after TVR and its adverse clinical outcomes. Methods: A retrospective study was conducted in 206 patients undergoing TVR under cardiopulmonary bypass from May 2005 to July 2021. According to the first postoperative defecation time after surgery, patients were divided into the delayed group (>3 days) and control group (≤3 days). Baseline characteristics and preoperative, intraoperative, and postoperative data were collected to investigate the clinical outcomes of defecation delay. Results: Among the 206 patients, 51.9% (107/206) cases were classified into the defecation delay group. Univariate analysis showed that age (P = 0.043), preoperative platelets (PLT) (P < 0.001), cardiopulmonary bypass (CPB) time (P = 0.013), minimum rectal temperature (P = 0.042), and the use of prokinetic drugs (P = 0.015) were significantly different in the two groups. In addition, the perioperative adverse events in the defecation delay group were significantly higher than that of the control group. Logistic regression analysis indicated that the mortality of patients was associated with postoperative renal dysfunction (P = 0.047) and postoperative respiratory failure (P = 0.004) but was not associated with defecation delay (P > 0.05). Conclusion: Patients with defecation delay after TVR were more likely to appear adverse events, however, defecation delay was not associated with mortality after TVR.